Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Mirikizumab, and IL-23 inhibitor. The original article is from gastroendonews.com.

Understanding the differences between Crohn’s and ulcerative colitis helps patients and caregivers recognize likely symptom patterns, know which tests and treatments are commonly used, and when to seek specialist care....

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.

Cure8 could only read part of this source from managedhealthcareexecutive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and...

This approval adds a newly authorized biologic option (mirikizumab/Omvoh) for adults with moderate-to-severe Crohn disease, including people who have not done well on steroids, immunomodulators, or prior biologics.

Cure8 found this source from marketscreener.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from webmd.com.

A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.

This announces a new FDA‑approved treatment (mirikizumab/Omvoh) for adults with moderately to severely active Crohn disease, offering another option for people who haven’t responded to prior therapies. The approval was...

A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy. The original article is from...

Based on the title and source metadata, this appears to be a patient education related to Diet and lifestyle. The original article is from msn.com.

An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...

An FDA approval means Omvoh is now an available biologic option for adults with Crohn’s disease, potentially expanding treatment choices. Payer decisions mentioned in the article could affect how quickly patients can...

This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...

A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...

A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.

A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...

This provides a new FDA‑approved biologic option (mirikizumab/Omvoh) for adults with moderate–severe Crohn's disease, including people who did not respond to prior therapies. The approval was based on Phase 3 trial...

FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may...

People with Crohn’s disease may be affected by the market trends that influence drug availability, costs, and development of new monitoring tools. Emerging monitoring technology could change how flare-ups are detected...

Cure8 found this source from markets.businessinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full...

Cure8 could only read part of this source from gurufocus.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative...

A new FDA approval means an additional biologic treatment option for adults with moderate to severe Crohn's disease. This may affect treatment choices and insurance coverage discussions for people with IBD.

Cure8 could only read part of this source from patientcareonline.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease and Community and awareness. The original article is from msn.com.

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Research and clinical trials.

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Mirikizumab. The original article is from firstwordpharma.com.

Cure8 could only read part of this source from endpts.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full details.

Cure8 found this source from wsj.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Medications. Open the original article for the full details.

Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

Cure8 found this source from reuters.com, but the page could not be read reliably yet. It is tagged for Medications. Open the original article for the full details.

This expands U.S. treatment options: Omvoh (mirikizumab) is now FDA‑approved for both major forms of IBD (ulcerative colitis and Crohn's disease), which may matter for people who haven’t responded to other therapies. The...

Cure8 could only read part of this source from ods.od.nih.gov, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle.

Patients with Crohn’s disease and other IBD forms may see new research directions aimed at blocking immune cell proliferation by targeting nucleotide metabolism. This is early-stage, preclinical work presented at a...

The story describes a new drug mechanism (dCK inhibition) that reduced inflammation in an IBD mouse model, which could point to a different way to target overactive immune cells in Crohn’s disease. It’s early-stage...

At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...

The article outlines complications of untreated Crohn’s that can become life threatening (sepsis, perforation, toxic megacolon, severe malnutrition, colorectal cancer). Knowing these risks helps people with Crohn’s...

Genetics can influence Crohn’s disease risk; knowing about risk genes and testing options may help people with a family history understand why disease runs in families and what testing can — and cannot — tell you. The...

This research uses patient-derived “mini-guts” to uncover epigenetic changes that may help explain differences between people with Crohn’s disease and could point to new biological pathways for future therapies.

Personal stories can help people with Crohn’s/IBD feel less alone and show how symptoms and delays in diagnosis can affect education, work and creative careers. The piece also highlights gaps in care (diagnostic delays...

A real-life story about living with Crohn’s, an ileostomy, and later having reversal surgery may be emotionally relevant and practically informative for people facing similar choices. It shows one path to regaining...

Based on the title and source metadata, this appears to be a patient story related to Community and awareness. The original article is from msn.com.